, Tracking Stock Market Picks
Enter Symbol:
Array Biopharma Inc. (ARRY) [hlAlert]

down 48.68 %

Array Biopharma Inc. (ARRY) rated Buy

Posted on: Tuesday,  Dec 4, 2007  9:25 AM ET by Morgan Joseph

Morgan Joseph rated Buy Array Biopharma Inc. (NASDAQ: ARRY) on 12/04/2007, when the stock price was $11.38. Since
then, Array Biopharma Inc. has lost 48.68% as of 01/15/2016's recent price of $5.84.
If you would have followed this Morgan Joseph's recommendation on ARRY, you would have lost 48.68% of your investment in 2964 days.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/4/2007 9:25 AM Buy
11.38 16.00
as of 8/27/2015
1 Week up  2.09 %
1 Month down  -26.07 %
3 Months down  -18.88 %
1 YTD up  16.56 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy